Everett Harris & Co. CA decreased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.3% during the fourth quarter, Holdings Channel reports. The firm owned 520,785 shares of the company’s stock after selling 7,062 shares during the quarter. Johnson & Johnson comprises about 1.0% of Everett Harris & Co. CA’s holdings, making the stock its 23rd biggest position. Everett Harris & Co. CA’s holdings in Johnson & Johnson were worth $75,316,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in JNJ. Clear Creek Financial Management LLC raised its holdings in shares of Johnson & Johnson by 25.1% in the 4th quarter. Clear Creek Financial Management LLC now owns 7,641 shares of the company’s stock valued at $1,105,000 after purchasing an additional 1,535 shares in the last quarter. Heck Capital Advisors LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $1,108,000. Austin Private Wealth LLC grew its holdings in shares of Johnson & Johnson by 18.7% in the fourth quarter. Austin Private Wealth LLC now owns 9,910 shares of the company’s stock valued at $1,433,000 after purchasing an additional 1,559 shares during the period. Great Diamond Partners LLC boosted its stake in Johnson & Johnson by 3.9% during the fourth quarter. Great Diamond Partners LLC now owns 3,319 shares of the company’s stock worth $480,000 after buying an additional 126 shares during the period. Finally, GFS Advisors LLC boosted its stake in Johnson & Johnson by 2.7% during the fourth quarter. GFS Advisors LLC now owns 52,190 shares of the company’s stock worth $7,548,000 after buying an additional 1,367 shares during the period. 69.55% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research firms have weighed in on JNJ. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Citigroup reduced their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Bank of America decreased their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Finally, Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $170.67.
Johnson & Johnson Stock Down 0.2 %
JNJ opened at $151.82 on Tuesday. The business has a 50 day moving average price of $147.61 and a 200 day moving average price of $156.12. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market cap of $365.53 billion, a P/E ratio of 22.83, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.29 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.27%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.
Insider Activity
In related news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Short Selling: How to Short a Stock
- How to Invest in Small Cap Stocks
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- These Are the Dividend Stocks Insiders Bought in January
- How Technical Indicators Can Help You Find Oversold Stocks
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.